Cerveau to develop Merck imaging agent for Alzheimer's Tau tangles

By Dani Bancroft contact

- Last updated on GMT

Cerveau to develop Merck imaging agent for Alzheimer’s Tau tangles
In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.

Cerveau Technologies Inc is a US clinical research organisation (CRO) which specialises in molecular imaging.

The Boston-based firm is the result of a partnership betwen Enigma Biomedical Group Inc in France and Sinotau Pharmaceutical Group in China.

With Alzheimer’s disease, an abnormal version of the Tau protein accumulates in the brain to form aggregates called neurofibrillary tangles.

Merck’s investigational agent – MK6240 – is being developed to image these Tau tangles using Positron Emission Tomography​ (PET) scanning.

A preclinical study​ of MK6240 reported the imaging agent works well in selecting and binding to neurofibrillary tangles, with Merck and Cerveau currently running a Phase I open-label trial​ scheduled to end this month.

Now, Cerveau has decided to fully license MK6240 for clinical development and commercialisation, announcing plans for a Phase III programme in 2018.

“There is a critical need for sensitive biomarkers for diagnosis and monitoring of tau pathology in neurodegenerative diseases,”​ said Darryle Schoepp VP of discovery at Merck Research Laboratories.

“[This is] to allow for more appropriate staging of disease states, and measuring the effect of candidate disease-modifying therapeutics.”

Merck will receive license fees, milestone payments and royalties on worldwide sales.

Feature Image: iStock/HASLOO

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers